# TPOXX® (tecovirimat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tecovirimat

> The FDA approved TPOXX® (tecovirimat), sponsored by SIGA TECHNOLOGIES INC (SIGA), on May 18, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TPOXX® (tecovirimat) |
| Codes |  |
| Sponsor | SIGA TECHNOLOGIES INC (SIGA) https://sec-api.dev/companies/siga/catalysts |
| Indications | [Smallpox](https://sec-api.dev/indications/smallpox) |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### July 13, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208627 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180713, review_priority PRIORITY; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208627%22

### November 23, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208627 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20211123, review_priority STANDARD; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208627%22

### May 18, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214518 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220518, review_priority STANDARD; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214518%22

### May 18, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208627 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220518, review_priority STANDARD; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208627%22

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Smallpox.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04957485 (Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-01 (ESTIMATED); Lead Sponsor SIGA Technologies." https://clinicaltrials.gov/study/NCT04957485

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Smallpox.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04957485 (Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-01 (ESTIMATED); Lead Sponsor SIGA Technologies." https://clinicaltrials.gov/study/NCT04957485

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tecovirimat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TPOXX® (tecovirimat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tecovirimat

```bibtex
@misc{secapidev_pdufa_tecovirimat_20261116,
  title        = {TPOXX® (tecovirimat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tecovirimat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tecovirimat_20261116","title":"TPOXX® (tecovirimat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tecovirimat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
